Bio Frontier Partners

BioTrove, Inc. specializes in micro and nano-scale technology platforms aimed at advancing life science and drug discovery research. The company has developed innovative systems that include the OpenArray platform, which facilitates relative gene expression analysis to support genomic research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove offers the RapidFire platform, designed for screening difficult drug targets through mass spectrometry-based assay development, alongside its RapidFire mass spectrometry hardware system that serves as a native detection technology for drug screening and in vitro absorption, distribution, metabolism, and excretion (ADME) applications. These technologies enable rapid and efficient analysis, enhancing the research process and fostering development in molecular diagnostics and high-throughput screening.

BioTrove, Inc. specializes in micro and nano-scale technology platforms aimed at advancing life science and drug discovery research. The company has developed innovative systems that include the OpenArray platform, which facilitates relative gene expression analysis to support genomic research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove offers the RapidFire platform, designed for screening difficult drug targets through mass spectrometry-based assay development, alongside its RapidFire mass spectrometry hardware system that serves as a native detection technology for drug screening and in vitro absorption, distribution, metabolism, and excretion (ADME) applications. These technologies enable rapid and efficient analysis, enhancing the research process and fostering development in molecular diagnostics and high-throughput screening.

CellZome is a pharmaceutical company based in Heidelberg, Baden-Württemberg, that specializes in the discovery, development, and commercialization of kinase-targeted drugs aimed at treating inflammatory diseases. Founded in 2000, the company focuses on creating a pipeline of kinase inhibitors that act on inflammatory mediators, offering oral therapeutic options for conditions such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma.

Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic and background/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California.

CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.

BioTrove, Inc. specializes in micro and nano-scale technology platforms aimed at advancing life science and drug discovery research. The company has developed innovative systems that include the OpenArray platform, which facilitates relative gene expression analysis to support genomic research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove offers the RapidFire platform, designed for screening difficult drug targets through mass spectrometry-based assay development, alongside its RapidFire mass spectrometry hardware system that serves as a native detection technology for drug screening and in vitro absorption, distribution, metabolism, and excretion (ADME) applications. These technologies enable rapid and efficient analysis, enhancing the research process and fostering development in molecular diagnostics and high-throughput screening.

AnGes MG, Inc. is a biopharmaceutical company with a mission to provide patients, especially those suffering from disease for which no effective therapy has been available to date, with innovative drugs. AnGes focuses on development of gene medicine, a next-generation biopharmaceutical. AnGes MG, Inc. was founded in December 1999 on an innovative discovery by researchers at Osaka University. AnGes already went through the first stage of research and development and is now in the second stage of commercialization. “Naglazyme®,” a drug for the treatment of mucopolysaccharidosis VI, an intractable disease, has already been marketed in Japan and HGF Plasmid (gene therapy) for the treatment of critical limb ischemia, which is a serious impairment of blood circulation in the legs, is in the last stage of clinical development. Development of “NF-κB decoy oligonucleotide,” a nucleic acid medicine that suppresses various types of inflammation including atopic dermatitis, disc degeneration, and medical device for prevention of vascular restenosis is also under way. Having started from research and development and now embarking on the new stage of practical application, AnGes strives to fulfill the expectations of patients, their families, shareholders, investors and the general public waiting for new drugs to be available and aims at becoming a “global leader in the field of gene medicine.”

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

CardioNet, Inc. (CardioNet) provides continuous, real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health. The Company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry (MCOT), event and Holter services. CardioNet's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes, which captures two-channel ECG data, measuring electrical activity of the heart. During the year ended December 31, 2010, it marketed its solution in 49 states. As of December 31, 2010, it had secured direct contracts with 304 commercial payors. On December 21, 2010, the Company completed the acquisition of Biotel Inc., and its wholly owned subsidiaries, Braemar, Inc. and Agility Centralized Research Services, Inc.